Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12

BACKGROUND: G47∆ is a triple-mutated oncolytic herpes simplex virus type 1 (HSV-1) recently approved as a new drug for malignant glioma in Japan. As the next-generation, we develop armed oncolytic HSV-1 using G47∆ as the backbone. Because oncolytic HSV-1 elicits specific antitumor immunity, interleu...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuhara, Hiroshi, Sato, Yuzuri Tsurumaki, Hou, Jiangang, Iwai, Miwako, Todo, Tomoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039936/
https://www.ncbi.nlm.nih.gov/pubmed/36966232
http://dx.doi.org/10.1038/s43856-023-00270-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039936/
https://www.ncbi.nlm.nih.gov/pubmed/36966232
http://dx.doi.org/10.1038/s43856-023-00270-4

Ejemplares similares